Table 2. Percent of Cells infected by Ad5G/L.
| 0 MOI (Percentage Population) | 10 MOI (Percentage Population) | 100 MOI (Percentage Population) | 1000 MOI (Percentage Population) | |
|---|---|---|---|---|
| NCF | 0.1 | 2.7 | 14.3 | 16 |
| HEK293 | 0.2 | 1.5 | 22.9 | 74.4 |
| CMT28 | 0.8 | 2.7 | 10.1 | 62.9 |
| CML7 | 0.4 | 1.1 | 11.1 | 74.8 |
| CML10 | 0.2 | 0.8 | 8.7 | 70.6 |
| DH82 | 0.3 | 0.5 | 6.2 | 55 |
| BR | 0.3 | 1.8 | 23.1 | 87.7 |
| MPT1 | 0.7 | 0.5 | 1.6 | 1.8 |
| OSW | 0.2 | 0.3 | 0.5 | 4.9 |
| 17–71 | 0.4 | 0.4 | 0.4 | 0.6 |
Quantitative GFP expression by non-cancerous (NCF, HEK293, and PBMC), non-hematopoietic origin cancer (DH82, CMT28, CML7, and CML10), and hematopoietic origin cancer (17–71, OSW, MPT-1, and BR) cells using BD Accuri™ C6 Cytometer software.